Pulmatrix, Inc. Files Q2 2024 10-Q Report
Ticker: PULM · Form: 10-Q · Filed: Aug 13, 2024 · CIK: 1574235
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
Pulmatrix 10-Q filed: Q2 2024 financials out. Check for updates.
AI Summary
Pulmatrix, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Pulmatrix, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Pulmatrix faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20240813 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Pulmatrix, Inc. (company) — Filer of the 10-Q report
- 20240630 (date) — End of the reporting period
- 20240813 (date) — Filing date of the report
- Ruthigen, Inc. (company) — Former name of Pulmatrix, Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on August 13, 2024.
What was Pulmatrix, Inc.'s former company name?
Pulmatrix, Inc.'s former company name was Ruthigen, Inc.
What is the Standard Industrial Classification (SIC) code for Pulmatrix, Inc.?
The SIC code for Pulmatrix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
In which state was Pulmatrix, Inc. incorporated?
Pulmatrix, Inc. was incorporated in Delaware (DE).
Filing Stats: 4,573 words · 18 min read · ~15 pages · Grade level 17.7 · Accepted 2024-08-13 09:20:23
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PULM The NASDAQ Stock Mar
Filing Documents
- form10-q.htm (10-Q) — 692KB
- ex10-4.htm (EX-10.4) — 53KB
- ex10-5.htm (EX-10.5) — 837KB
- ex10-6.htm (EX-10.6) — 127KB
- ex31-1.htm (EX-31.1) — 12KB
- ex32-1.htm (EX-32.1) — 4KB
- ex10-4_002.jpg (GRAPHIC) — 1367KB
- 0001493152-24-031478.txt ( ) — 6648KB
- pulm-20240630.xsd (EX-101.SCH) — 34KB
- pulm-20240630_cal.xml (EX-101.CAL) — 48KB
- pulm-20240630_def.xml (EX-101.DEF) — 133KB
- pulm-20240630_lab.xml (EX-101.LAB) — 262KB
- pulm-20240630_pre.xml (EX-101.PRE) — 198KB
- form10-q_htm.xml (XML) — 463KB
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited) 1 Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 1 Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 2 Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2024 and 2023 3 Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.
Controls and Procedures
Controls and Procedures 25
—OTHER INFORMATION
PART II—OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 25 Item 1A.
Risk Factors
Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 26
SIGNATURES
SIGNATURES 27 i PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements. PULMATRIX, INC. Consolidated Balance Sheets (in thousands, except share and per share data) June 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 12,379 $ 19,173 Restricted cash 1,421 - Accounts receivable 635 928 Prepaid expenses and other current assets 1,201 742 Total current assets 15,636 20,843 Property and equipment, net - 1,158 Operating lease right-of-use asset - 10,309 Long-term restricted cash 51 1,472 Other long-term assets 93 176 Total assets $ 15,780 $ 33,958 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 393 $ 1,915 Accrued expenses and other current liabilities 1,783 947 Operating lease liability 24 429 Deferred revenue 270 618 Total current liabilities 2,470 3,909 Deferred revenue, net of current portion - 3,727 Operating lease liability, net of current portion - 8,327 Total liabilities 2,470 15,963 Commitments and contingencies (Note 10) - - Stockholders' equity: Preferred Stock, $ 0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at June 30, 2024 and December 31, 2023 - - Common stock, $ 0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at June 30, 2024 and December 31, 2023 - - Additional paid-in capital 305,893 305,592 Accumulated deficit ( 292,583 ) ( 287,597 ) Total stockholders' equity 13,310 17,995 Total liabilities and stockholders' equity $ 15,780 $ 33,958 The accompanying footnotes are an integral part of these condensed consolidated financial statements. 1 PULMATRIX, INC. Consolidated (in thousands, except share and per share data) (unaudited) 2024 2023 2024 2023 Three M